Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C P Cannon

Showing results (71-80 of 149) with videos related to

Pageof 15
Sort By:
Heart (British Cardiac Society)|September 18, 2014
Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapyM Janzon, S James, C P Cannon, et al.
The American Journal of Cardiology|June 17, 2000
Degree of residual stenosis in the culprit coronary artery after thrombolytic administration (Thrombolysis In Myocardial Infarction [TIMI] trials)J Llevadot, R P Giugliano, C H McCabe, et al.
Journal of the American College of Cardiology|June 17, 1998
C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial InfarctionD A Morrow, N Rifai, E M Antman, et al.
Journal of the American College of Cardiology|February 17, 2000
Serum amyloid A predicts early mortality in acute coronary syndromes: A TIMI 11A substudyD A Morrow, N Rifai, E M Antman, et al.
Circulation|April 8, 1998
Prospective temporal analysis of the onset of preinfarction angina versus outcome: an ancillary study in TIMI-9BR A Kloner, T Shook, E M Antman, et al.
Journal of Clinical Pharmacology|May 12, 2000
Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarctionN B Modi, N L Fox, F W Clow, et al.
The American Journal of Cardiology|September 8, 2001
The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarctionP F Bray, C P Cannon, P Goldschmidt-Clermont, et al.
Journal of Thrombosis and Haemostasis : JTH|January 26, 2010
G-protein beta3 subunit polymorphism and bleeding in the orbofiban in patients with unstable coronary syndromes-thrombolysis in myocardial infarction 16 trialA O Maree, C Vangjeli, H Jneid, et al.
The American Journal of Cardiology|February 17, 2001
Can we replace the 90-minute thrombolysis in myocardial infarction (TIMI) flow grades with those at 60 minutes as a primary end point in thrombolytic trials? TIMI Study GroupC M Gibson, S A Murphy, S J Marble, et al.
The American Journal of Cardiology|August 15, 1995
Impact of a thrombolysis research trial on time to treatment for acute myocardial infarction in the emergency departmentC R Boisjolie, S W Sharkey, C P Cannon, et al.
Pageof 15

Showing results (71-80 of 149) with videos related to

Sort By:
Pageof 15
Heart (British Cardiac Society)|September 18, 2014
Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapyM Janzon, S James, C P Cannon, et al.
The American Journal of Cardiology|June 17, 2000
Degree of residual stenosis in the culprit coronary artery after thrombolytic administration (Thrombolysis In Myocardial Infarction [TIMI] trials)J Llevadot, R P Giugliano, C H McCabe, et al.
Journal of the American College of Cardiology|June 17, 1998
C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial InfarctionD A Morrow, N Rifai, E M Antman, et al.
Journal of the American College of Cardiology|February 17, 2000
Serum amyloid A predicts early mortality in acute coronary syndromes: A TIMI 11A substudyD A Morrow, N Rifai, E M Antman, et al.
Circulation|April 8, 1998
Prospective temporal analysis of the onset of preinfarction angina versus outcome: an ancillary study in TIMI-9BR A Kloner, T Shook, E M Antman, et al.
Journal of Clinical Pharmacology|May 12, 2000
Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarctionN B Modi, N L Fox, F W Clow, et al.
The American Journal of Cardiology|September 8, 2001
The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarctionP F Bray, C P Cannon, P Goldschmidt-Clermont, et al.
Journal of Thrombosis and Haemostasis : JTH|January 26, 2010
G-protein beta3 subunit polymorphism and bleeding in the orbofiban in patients with unstable coronary syndromes-thrombolysis in myocardial infarction 16 trialA O Maree, C Vangjeli, H Jneid, et al.
The American Journal of Cardiology|February 17, 2001
Can we replace the 90-minute thrombolysis in myocardial infarction (TIMI) flow grades with those at 60 minutes as a primary end point in thrombolytic trials? TIMI Study GroupC M Gibson, S A Murphy, S J Marble, et al.
The American Journal of Cardiology|August 15, 1995
Impact of a thrombolysis research trial on time to treatment for acute myocardial infarction in the emergency departmentC R Boisjolie, S W Sharkey, C P Cannon, et al.
Pageof 15